Advertisement

Expert Point of View: Guido Reifenberger, MD



I was impressed by this first study of dabrafenib in pediatric patients with BRAF V600E–mutated relapsed, refractory low-grade glioma.
— Guido Reifenberger, MD

“Low-grade gliomas are biologically and clinically heterogeneous entities with different genetic drivers,” said formal discussant of this trial, Guido Reifenberger, MD, of Heinrich Heine University, Düsseldorf, ­Germany.

“The BRAF V600 mutation is a novel therapeutic target in gliomas occurring in a subset of tumors. Anecdotal evidence and case reports suggest that BRAF inhibitors that target the V600E mutation are effective. I was impressed by this first study of dabrafenib in pediatric patients with BRAF V600E–mutated relapsed, refractory low-grade glioma,” Dr. Reifenberger told listeners.

“This was only a one-arm study, but these are promising data from the first prospective study of dabrafenib in this subgroup of pediatric patients,” he said. ■

Disclosure: Dr. Reifenberger has received research grants from Roche and Merck.


Related Articles

Preliminary Data Indicate Potential Role for Dabrafenib as Part of Therapy for Pediatric Low-Grade Gliomas With BRAF V600 Mutation

About 10% of children with low-grade gliomas have the BRAF V600E mutation, and preliminary studies suggest that the BRAF inhibitor dabrafenib (Tafinlar) may play an important role in treating this group of patients. A phase I/II trial presented at the 2016 European Society for Medical Oncology...


Advertisement

Advertisement



Advertisement

click me